Boehringer Ingelheim Pharmaceuticals, INC.

pharmaceutical company

Based in CT

🤖

AI Overview

With $1.5M in lobbying spend across 29 quarterly filings, Boehringer Ingelheim Pharmaceuticals, INC is a significant lobbying presence. Their lobbying covers 3 issue areas. Active from 2018 to 2025.

$1.5M

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2018	$200K
2019	$100K
2020	$200K
2021	$150K
2022	$250K
2023	$200K
2024	$260K
2025	$150K

Issues Lobbied

Health Issues Foreign Relations Medicare/Medicaid

Lobbying Firms

Thorn Run Partners

Lobbyists

Andrew Rosenberg Gary Palmquist Charles Thomas Beau Schuyler Paul Bock Harriet Melvin

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Foreign Relations, Medicare/Medicaid

Cost Sharing (Preserving Access to Medicines). Healthcare Exchanges. Average Sales Price. Reimbursements. Children's Health Insurance Program (CHIP). Brand safety and security.

Legislation related to CFIUS and FARA including issues related to critical technologies and export controls; S.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017; S.2482, Foreign Agents Registration Amendments Act of 2018.

Rebates for dual eligible and low-income subsidy population in Medicare Part D. Non-Interference. Implementation of the 21st Century Cures Act (P.L.114-255). ADUFA Reauthorization.

Part D coverage gap and the Medicare reimbursement of biosimilars; H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123); H.R.1625, Consolidated Appropriations Act, 2018 (P.L.115-141).

Value Based Contracting.

Brand safety and security.

Legislation related to CFIUS and FARA including issues related to critical technologies and export controls;

S.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017;

S.2482, Foreign Agents Registration Amendments Act of 2018.

Rebates for dual eligible and low-income subsidy population in Medicare Part D.

Non-Interference.

Implementation of the 21st Century Cures Act (P.L.114-255).

ADUFA Reauthorization.

Part D coverage gap and the Medicare reimbursement of biosimilars.

Issues related to Value Based contracting, brand safety and security.

Issues related to Medicare and Medicaid reimbursement for pharmaceuticals.